MARCY PENROD: Open Payments
NPI 1699318592 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$232 in 11 payments from 7 companies in 2025. Trend: 2023 $377 · 2024 $216 · 2025 $232
Food & beverage: $232
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $79 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| CVRx, Inc. | 1 | $29 |
| PFIZER INC. | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
| Abbott Laboratories | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
Products named: REPATHA, LEQVIO, Barostim Neo System, VYNDAQEL, Kerendia, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, LOKELMA.
Industry payments across IN — which companies pay providers there.
